trial

A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia

NCTId NCT00743847
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2009-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-03
Primary completion
2009-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Varenicline

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

0 total

Linked catalysts

1
A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In S — primary completion2009-11

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2009-11
Status
WITHDRAWN
relationships
The graph out of here
drug
Varenicline
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication